INTRODUCTION: Germline silencing of the PD-related protein LRRK2 does not alter glutamate or dopamine release in adult mice, but some exploratory abnormalities have been reported with ageing. Contrastingly, high levels of human LRRK2 cause locomotor alterations and cognitive deficits accompanied by reduced striatal dopamine levels, with the latter also observed in G2019S mutant mice. Comparative cognitive and motor behavioral testing of LRRK2 KO, overexpressor and mutant overexpressor mice has not previously been reported. METHODS: Parallel, comparative behavioral characterization was performed assessing motor and cognitive abilities. Striatal antisense oligonucleotide injections were conducted to investigate the effects of acute LRRK2 silencing on behavior and dopamine fiber density. Striatal synaptosomes prepared from hG2019S mice assessed vesicular release of dopamine and its sensitivity to D2 autoreceptor stimulation. RESULTS: Genetic ablation of LRRK2 has no long-term consequences on motor or cognitive function. Consistently, no effects on behavior or dopaminergic fiber density were observed following acute striatal silencing. Conversely, 12-month OE mice show persistent locomotor deficits and worsening of cognitive abilities; whereas, hG2019S mice display early hyperactivity and effective learning and memory that progress to decreased motor and cognitive deficits at older ages. The G2019S mutation does not affect vesicular dopamine release, but decreases its sensitivity to D2-mediated inhibition. CONCLUSION: LRRK2 silencing is well tolerated in mouse, arguing PD does not result from LRRK2 loss of function. High levels of WT and G2019S LRRK2 produce similar but temporally distinct phenotypes, potentially modeling different stages of disease progression. The data implicate gain of LRRK2 function in the pathogenesis of PD.
INTRODUCTION: Germline silencing of the PD-related protein LRRK2 does not alter glutamate or dopamine release in adult mice, but some exploratory abnormalities have been reported with ageing. Contrastingly, high levels of humanLRRK2 cause locomotor alterations and cognitive deficits accompanied by reduced striatal dopamine levels, with the latter also observed in G2019S mutant mice. Comparative cognitive and motor behavioral testing of LRRK2 KO, overexpressor and mutant overexpressor mice has not previously been reported. METHODS: Parallel, comparative behavioral characterization was performed assessing motor and cognitive abilities. Striatal antisense oligonucleotide injections were conducted to investigate the effects of acute LRRK2 silencing on behavior and dopamine fiber density. Striatal synaptosomes prepared from hG2019S mice assessed vesicular release of dopamine and its sensitivity to D2 autoreceptor stimulation. RESULTS: Genetic ablation of LRRK2 has no long-term consequences on motor or cognitive function. Consistently, no effects on behavior or dopaminergic fiber density were observed following acute striatal silencing. Conversely, 12-month OE mice show persistent locomotor deficits and worsening of cognitive abilities; whereas, hG2019S mice display early hyperactivity and effective learning and memory that progress to decreased motor and cognitive deficits at older ages. The G2019S mutation does not affect vesicular dopamine release, but decreases its sensitivity to D2-mediated inhibition. CONCLUSION:LRRK2 silencing is well tolerated in mouse, arguing PD does not result from LRRK2 loss of function. High levels of WT and G2019SLRRK2 produce similar but temporally distinct phenotypes, potentially modeling different stages of disease progression. The data implicate gain of LRRK2 function in the pathogenesis of PD.
Authors: Manish Verma; Jason Callio; P Anthony Otero; Israel Sekler; Zachary P Wills; Charleen T Chu Journal: J Neurosci Date: 2017-10-16 Impact factor: 6.167
Authors: Samuel O Adeosun; Xu Hou; Baoying Zheng; Heather L Melrose; Thomas Mosley; Jun Ming Wang Journal: Neurobiol Learn Mem Date: 2017-05-06 Impact factor: 2.877
Authors: Yulan Xiong; Stewart Neifert; Senthilkumar S Karuppagounder; Qinfang Liu; Jeannette N Stankowski; Byoung Dae Lee; Han Seok Ko; Yunjong Lee; Jonathan C Grima; Xiaobo Mao; Haisong Jiang; Sung-Ung Kang; Deborah A Swing; Lorraine Iacovitti; Lino Tessarollo; Ted M Dawson; Valina L Dawson Journal: Proc Natl Acad Sci U S A Date: 2018-01-31 Impact factor: 11.205
Authors: Bridget A Matikainen-Ankney; Nebojsa Kezunovic; Caroline Menard; Meghan E Flanigan; Yue Zhong; Scott J Russo; Deanna L Benson; George W Huntley Journal: J Neurosci Date: 2018-09-24 Impact factor: 6.167
Authors: Melissa Conti Mazza; Victoria Nguyen; Alexandra Beilina; Ema Karakoleva; Michael Coyle; Jinhui Ding; Christopher Bishop; Mark R Cookson Journal: J Parkinsons Dis Date: 2021 Impact factor: 5.520
Authors: Mattia Volta; Dayne A Beccano-Kelly; Sarah A Paschall; Stefano Cataldi; Sarah E MacIsaac; Matthew J Farrer; Austen J Milnerwood; Naila Kuhlmann; Chelsie A Kadgien; Igor Tatarnikov; Jesse Fox; Jaskaran Khinda; Emma Mitchell; Sabrina Bergeron; Heather Melrose Journal: Elife Date: 2017-09-20 Impact factor: 8.140